A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.

MLA

Yamauchi, Takahiro, et al. “A Nelarabine-Resistant T-Lymphoblastic Leukemia CCRF-CEM Variant Cell Line Is Cross-Resistant to the Purine Nucleoside Phosphorylase Inhibitor Forodesine.” Anticancer Research, vol. 34, no. 9, Sept. 2014, pp. 4885–92. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25202070&authtype=sso&custid=ns315887.

APA

Yamauchi, T., Uzui, K., Nishi, R., Tasaki, T., & Ueda, T. (2014). A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine. Anticancer Research, 34(9), 4885–4892.

Chicago

Yamauchi, Takahiro, Kanako Uzui, Rie Nishi, Toshiki Tasaki, and Takanori Ueda. 2014. “A Nelarabine-Resistant T-Lymphoblastic Leukemia CCRF-CEM Variant Cell Line Is Cross-Resistant to the Purine Nucleoside Phosphorylase Inhibitor Forodesine.” Anticancer Research 34 (9): 4885–92. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=25202070&authtype=sso&custid=ns315887.